A Phase 2 interventional study of Belantamab mafodotin in Multiple Myeloma, sponsored by GlaxoSmithKline. Completed at 77 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 7th largest by enrollment, is one of 10 that started in 2022, is one of 12 in phase 2, and was the 22nd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
PrECOG, LLC. · Sites in United States
Ages 18–79
GlaxoSmithKline · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
By country, each count listing its studies:
belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 29 · Phase 3 9
First in 2014; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 177 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 49 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 49 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
42 studies in Multiple Myeloma by GlaxoSmithKline: 6 open now, 20 under way, 7 of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 42 studies in Multiple Myeloma by GlaxoSmithKline, this one is the 10th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2022, is one of 9 in phase 2, and was the 26th registered.
GlaxoSmithKline’s Multiple Myeloma studies by the year they started, since 2006.
4 of the studies testing belantamab mafodotin in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT03715478Canadian Myeloma Research GroupMulti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | 2027-06-01 |
| NCT05556798Memorial Sloan Kettering Cancer CenterA Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | 2027-10 |
| NCT05208307Emory UniversityBelantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | 2027-10-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, from their registry updates:
Among GlaxoSmithKline’s 42 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Belantamab mafodotin
Drug: Belantamab mafodotin
Drug: Belantamab mafodotin
Drug: Belantamab mafodotin
Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.
Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale
The KVA scale is based on the evaluation of corneal changes using slit lamp examination. This scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
Time frame: Up to 29.5 months
Number of Participants With Corneal Events up to Week 16
The number of participants with corneal events were assessed using KVA scale. The KVA scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
Time frame: Up to week 16
Incidence Rate of Corneal Events by Grade (KVA Scale)
Incidence rate of corneal events is defined as the percentage of participants with corneal events by grade according to the KVA scale. The KVA scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
Time frame: Up to 152 weeks
Exposure Adjusted Incidence Rate of Corneal Events as Per CTCAE Grade
Exposure adjusted incidence rate of corneal events is defined as the number of participants with corneal events divided by the total exposure time for all participants at risk in the treatment group. Incidence rate for corneal events was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity. The number of participants with Grades 3,4, and 5 are presented.
Time frame: Up to 152 weeks
Median Duration of All the Dose Delays
Median duration of dose delays is defined as the median duration in time of all the dose delays in the respective treatment group. Duration of delays is defined as period from the expected start date of dose to actual start date of current dose.
Time frame: Up to 152 weeks
Percentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Corneal Events
The percentage of participants that required dose reduction, dose interruption/delay, permanent treatment discontinuation due to corneal events were evaluated using KVA Scale. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
Time frame: Up to 152 weeks
Cumulative Incidence of Grade 2 or Above Corneal Events (KVA Scale)
Cumulative incidence of Grade 2 or above corneal events is defined as the percentage of corneal events of Grade 2 or above, as assessed using the KVA scale, within a specific time interval. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
Time frame: At 3 months, 6 months, 9 months and 12 months
Toxicity Index (TI)
Toxicity Index is a composite score derived from the severity grades of adverse events (AEs) reported during the study, based on the Common Terminology Criteria for Adverse Events (CTCAE). A participant's score is calculated as a function of the ordered toxicity grades, represented in descending order by sequence, on a scale of 0-6, where 0 represents no toxicity and 6 represents the highest toxicity. CTCAE grades are defined as follows: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe or medically significant but not immediately life-threatening), Grade 4 (Life-threatening consequences), and Grade 5 (Death related to AE). Higher grades indicate greater toxicity severity.
Time frame: Up to 152 weeks
Duration of Corneal Events of Grade 2 or Above
Duration of corneal events is defined for each participant as the sum of duration of all the corneal AEs. The duration is defined as time from onset of any corneal events (KVA scale) of Grade 2 or above to the first time resolution to baseline, Grade 1 or below. It required at least one day gap between the resolution of all events from first occurrence to the onset of next occurrence.
Time frame: Up to 152 weeks
Percentage of Time on Study With Grade 2 or Above Corneal Events
It is defined as the percentage of time that a participant has corneal events out of the total time that a participant is on the study. Time with corneal events is defined as time from onset of any corneal events (KVA scale) of Grade 2 or above to the first-time resolution to baseline, Grade 1 or below.
Time frame: Up to 152 weeks
Number of Participants With Change in Best Corrected Visual Acuity Test (BCVA) Scores
Change in BCVA is defined as change in logarithm of the minimum angle of resolution (logMAR) units compared with baseline or the first visit after the cataract surgery. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any change from baseline categories is presented for right and left eyes. No change/improved vision is defined as a change from baseline \<0.1; a possible worsened vision is defined as a change from baseline \>=0.1 to \<=0.3; a definite worsened vision is defined as a change from baseline \>0.3 logMAR score. Improvement in BCVA is represented by a reduction in logMAR score from baseline, while worsening in BCVA is represented by an increase in logMAR score from baseline.
Time frame: Baseline (Day 1) and up to 152 weeks
Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.
Time frame: Up to 152 weeks
Percentage of Participants With a Confirmed VGPR or Better (i.e., VGPR, CR, and sCR)
Percentage of participants with a confirmed VGPR or better defined as percentage of participant with confirmed VGPR, CR, and sCR, according to the 2016 IMWG response criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h.
Time frame: Up to 152 weeks
Time to Response (TTR)
TTR defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better), according to the 2016 IMWG response criteria. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.
Time frame: Up to 152 weeks
Duration of Response (DoR)
DoR defined as the time from first documented evidence of PR or better until disease progression (PD) among responders according to the 2016 IMWG response criteria or death due to any cause. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).
Time frame: Up to 152 weeks
Time to Progression (TTP)
TTP defined as the time from randomization until the earliest date of documented PD or death due to PD, according to the 2016 IMWG response criteria. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).
Time frame: Up to 152 weeks
Progression Free Survival (PFS)
PFS defined as the time from randomization until the earliest date of documented PD, according to the 2016 IMWG response criteria, or death due to any cause. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).
Time frame: Up to 152 weeks
Overall Survival (OS)
OS defined as the time from randomization until the date of death due to any cause.
Time frame: Up to 152 weeks
Percentage of Participants With AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs were coded using the standard Medical Dictionary for Regulatory Activities (MedDRA).
Time frame: Up to 152 weeks
Percentage of Participants Requiring Dose Reduction, Dose Interruption/Delay, Permanent Treatment Discontinuation Due to Any AEs
Percentage of participants requiring dose reduction, dose interruption/delay, permanent treatment discontinuation due to any AEs were presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs were coded using the standard MedDRA.
Time frame: Up to 152 weeks
Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Blood samples were collected for the analysis of hematology parameters. The parameters were graded according to CTCAE grades. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases in grade 1/2/3 to a grade of 4 are presented.
Time frame: Up to 152 weeks
Number of Participants With Worst-Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Blood samples were collected for the analysis of clinical chemistry parameters. The parameters were graded according to CTCAE grades. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases in grade 1/2/3 to a grade of 4 are presented.
Time frame: Up to 152 weeks
Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1) and up to 152 weeks
Titers of ADAs Against Belantamab Mafodotin
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
Time frame: Up to 152 weeks
Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC)
Plasma samples were collected for PK analysis for belantamab mafodotin antibody-drug conjugate (ADC).
Time frame: Cycle(C)1 Day(D) 1 Pre-dose, End of Infusion (EOI), Start of Infusion (SOI) + 2 hours (H); C1D2 SOI+24H; C1D4; C1D8-15
Concentration at 21 Days for Belantamab Mafodotin ADC
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
Time frame: At 21 days
Average Concentration Over 21 Days (Cavg) for Belantamab Mafodotin ADC
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15, D21
Area Under the Concentration-time Curve (AUC) (0-504h) of Belantamab Mafodotin ADC
Plasma samples were collected to determine the area under the concentration-time curve (AUC) (0-504h) of Belantamab mafodotin ADC.
Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15, D21
Half-life (t1/2) of Belantamab Mafodotin ADC
Plasma samples were collected for PK analysis of Belantamab mafodotin ADC
Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Clearance (CL) for Belantamab Mafodotin ADC
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
Steady-state Volume of Distribution (Vss) for Belantamab Mafodotin ADC
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
Time frame: C1 D1 Pre-dose, EOI, SOI + 2H; C1D2 SOI+24H; C1D4; C1D8-15
| Milestone | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Started | 40 | 40 | 40 | 40 | 17 |
| Safety | 39 | 40 | 39 | 40 | 17 |
| Pharmacokinetic | 38 | 41 | 39 | 40 | 17 |
| Completed | 10 | 7 | 8 | 9 | 7 |
| Not completed | 30 | 33 | 32 | 31 | 10 |
| Withdrew: Death | 23 | 23 | 25 | 21 | 5 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 2 | 0 |
| Withdrew: Physician decision | 1 | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 5 | 3 | 6 | 3 |
| Withdrew: Ongoing at the time of analysis | 1 | 2 | 2 | 2 | 2 |
The KVA scale is based on the evaluation of corneal changes using slit lamp examination. This scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
| Percentage of participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W |
|---|---|---|---|---|
| Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale | 64 | 40 | 44 | 38 |
The number of participants with corneal events were assessed using KVA scale. The KVA scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
| Participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Number of Participants With Corneal Events up to Week 16 | 26 | 25 | 23 | 24 | 12 |
Incidence rate of corneal events is defined as the percentage of participants with corneal events by grade according to the KVA scale. The KVA scale provides a standardized approach for evaluating the relationship between corneal health and visual acuity. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
| Percentage of participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Grade 1 | 3 | 10 | 7 | 10 | 2 |
| Grade 2 | 10 | 4 | 5 | 6 | 3 |
| Grade 3 | 15 | 9 | 11 | 9 | 6 |
| Grade 4 | 0 | 3 | 1 | 0 | 2 |
Exposure adjusted incidence rate of corneal events is defined as the number of participants with corneal events divided by the total exposure time for all participants at risk in the treatment group. Incidence rate for corneal events was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity. The number of participants with Grades 3,4, and 5 are presented.
| Events per 100 patient years | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Grade 3 | 4 | 2 | 4 | 0 | 3 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 |
Median duration of dose delays is defined as the median duration in time of all the dose delays in the respective treatment group. Duration of delays is defined as period from the expected start date of dose to actual start date of current dose.
| Days | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Median Duration of All the Dose Delays | 39.0 (16 to 144) | 18.0 (4 to 125) | 51.0 (18 to 163) | 60.0 (34 to 103) | 59.0 (25 to 88) |
The percentage of participants that required dose reduction, dose interruption/delay, permanent treatment discontinuation due to corneal events were evaluated using KVA Scale. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
| Percentage of participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Dose Reduction | 31 | 28 | 26 | 23 | 35 |
| Dose Interruption/Delay | 59 | 35 | 28 | 33 | 29 |
| Permanent Treatment Discontinuation | 0 | 3 | 0 | 0 | 6 |
Cumulative incidence of Grade 2 or above corneal events is defined as the percentage of corneal events of Grade 2 or above, as assessed using the KVA scale, within a specific time interval. KVA scale is defined as Grade 0: No keratopathy, normal visual acuity with no corneal abnormalities; Grade 1: Mild changes to the cornea with no significant loss in visual acuity; Grade 2: Moderate corneal changes with noticeable visual acuity reduction; Grade 3: Severe corneal changes with substantial visual acuity impairment; Grade 4: Very severe corneal changes leading to significant vision loss. Higher grade indicates greater severity of corneal events.
| Percentage of events | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| At 3 months | 59 | 32 | 36 | 33 | 53 |
| At 6 months | 64 | 37 | 41 | 38 | 59 |
| At 9 months | 64 | 40 | 41 | 38 | 59 |
| At 12 months | 64 | 40 | 44 | 38 | 59 |
Toxicity Index is a composite score derived from the severity grades of adverse events (AEs) reported during the study, based on the Common Terminology Criteria for Adverse Events (CTCAE). A participant's score is calculated as a function of the ordered toxicity grades, represented in descending order by sequence, on a scale of 0-6, where 0 represents no toxicity and 6 represents the highest toxicity. CTCAE grades are defined as follows: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe or medically significant but not immediately life-threatening), Grade 4 (Life-threatening consequences), and Grade 5 (Death related to AE). Higher grades indicate greater toxicity severity.
| Score on scale | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Toxicity Index (TI) | 3.68 ± 1.078 | 3.83 ± 1.017 | 3.87 ± 1.092 | 3.43 ± 1.031 | 3.64 ± 0.892 |
Duration of corneal events is defined for each participant as the sum of duration of all the corneal AEs. The duration is defined as time from onset of any corneal events (KVA scale) of Grade 2 or above to the first time resolution to baseline, Grade 1 or below. It required at least one day gap between the resolution of all events from first occurrence to the onset of next occurrence.
| Days | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Duration of Corneal Events of Grade 2 or Above | 63.0 (22 to 296) | 67.5 (13 to 233) | 46.5 (20 to 162) | 53.5 (20 to 148) | 44.0 (21 to 274) |
It is defined as the percentage of time that a participant has corneal events out of the total time that a participant is on the study. Time with corneal events is defined as time from onset of any corneal events (KVA scale) of Grade 2 or above to the first-time resolution to baseline, Grade 1 or below.
| Percentage of Time | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Percentage of Time on Study With Grade 2 or Above Corneal Events | 23.27 (0.5 to 76.7) | 24.86 (5.1 to 69.1) | 18.99 (0.4 to 78.1) | 23.67 (5.5 to 85.6) | 35.63 (3.9 to 61.6) |
Change in BCVA is defined as change in logarithm of the minimum angle of resolution (logMAR) units compared with baseline or the first visit after the cataract surgery. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any change from baseline categories is presented for right and left eyes. No change/improved vision is defined as a change from baseline \<0.1; a possible worsened vision is defined as a change from baseline \>=0.1 to \<=0.3; a definite worsened vision is defined as a change from baseline \>0.3 logMAR score. Improvement in BCVA is represented by a reduction in logMAR score from baseline, while worsening in BCVA is represented by an increase in logMAR score from baseline.
| Participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Left Eye — No change | 16 | 20 | 19 | 27 | 8 |
| Left Eye — Possible worsened vision | 2 | 3 | 3 | 1 | 1 |
| Left Eye — Definite worsened vision | 4 | 1 | 1 | 1 | 2 |
| Right Eye — No change | 16 | 18 | 21 | 27 | 10 |
| Right Eye — Possible worsened vision | 4 | 5 | 2 | 2 | 1 |
| Right Eye — Definite worsened vision | 1 | 1 | 0 | 0 | 0 |
ORR was defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.
| Percentage of participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 33 (18.6 to 49.1) | 25 (12.7 to 41.2) | 28 (14.6 to 43.9) | 25 (12.7 to 41.2) | 18 (3.8 to 43.4) |
Percentage of participants with a confirmed VGPR or better defined as percentage of participant with confirmed VGPR, CR, and sCR, according to the 2016 IMWG response criteria. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h.
| Percentage of participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Percentage of Participants With a Confirmed VGPR or Better (i.e., VGPR, CR, and sCR) | 25 (12.7 to 41.2) | 18 (7.3 to 32.8) | 8 (1.6 to 20.4) | 15 (5.7 to 29.8) | 18 (3.8 to 43.4) |
TTR defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (i.e., confirmed PR or better), according to the 2016 IMWG response criteria. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.
| Months | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Time to Response (TTR) | 0.8 (0.7 to 1.4) | 1.1 (0.7 to 2.1) | 0.7 (0.7 to 0.9) | 0.8 (0.7 to 2.2) | 1.5 (0.8 to NA) |
DoR defined as the time from first documented evidence of PR or better until disease progression (PD) among responders according to the 2016 IMWG response criteria or death due to any cause. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).
| Months | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Duration of Response (DoR) | 15.9 (4.9 to 21.4) | 22.1 (4.2 to NA) | 6.2 (2.1 to 20.7) | 7.8 (2.8 to 13.3) | 15.9 (NA to NA) |
TTP defined as the time from randomization until the earliest date of documented PD or death due to PD, according to the 2016 IMWG response criteria. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).
| Months | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Time to Progression (TTP) | 6.0 (2.8 to 10.4) | 2.1 (1.0 to 9.1) | 2.8 (1.7 to 4.2) | 2.7 (1.9 to 5.6) | 2.9 (0.8 to 17.3) |
PFS defined as the time from randomization until the earliest date of documented PD, according to the 2016 IMWG response criteria, or death due to any cause. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h).
| Months | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 5.7 (2.8 to 9.0) | 2.1 (1.0 to 3.6) | 2.8 (1.4 to 3.5) | 2.7 (1.9 to 4.2) | 2.8 (0.8 to 17.3) |
OS defined as the time from randomization until the date of death due to any cause.
| Months | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Overall Survival (OS) | 20.9 (8.1 to NA) | 15.0 (7.6 to 20.1) | 13.5 (7.5 to 21.2) | 14.5 (7.7 to NA) | NA (4.8 to NA) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs were coded using the standard Medical Dictionary for Regulatory Activities (MedDRA).
| Percentage of participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Percentage of Participants With AEs | 100 | 100 | 100 | 100 | 100 |
Percentage of participants requiring dose reduction, dose interruption/delay, permanent treatment discontinuation due to any AEs were presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs were coded using the standard MedDRA.
| Percentage of participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Dose Reduction | 8 | 13 | 5 | 5 | 18 |
| Dose Interruption/Delay | 31 | 23 | 13 | 10 | 35 |
| Permanent Treatment Discontinuation | 10 | 8 | 10 | 5 | 18 |
Blood samples were collected for the analysis of hematology parameters. The parameters were graded according to CTCAE grades. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases in grade 1/2/3 to a grade of 4 are presented.
| Participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Eosinophilia, Increase to Grades 1 to 4 | 3 | 1 | 2 | 1 | 0 |
| Eosinophilia, Increase to Grades 2 to 4 | 0 | 0 | 0 | 0 | 0 |
| Eosinophilia, Increase to Grades 3 to 4 | 0 | 0 | 0 | 0 | 0 |
| Anemia, Increase to Grades 1 to 4 | 17 | 15 | 20 | 15 | 6 |
| Anemia, Increase to Grades 2 to 4 | 16 | 14 | 17 | 14 | 5 |
| Anemia, Increase to Grades 3 to 4 | 10 | 9 | 11 | 9 | 4 |
| Hemoglobin increased, Increase to Grades 1 to 4 | 1 | 1 | 0 | 0 | 0 |
| Hemoglobin increased, Increase to Grades 2 to 4 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased, Increase to Grades 3 to 4 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis, Increase to Grades 1 to 4 | 2 | 0 | 0 | 0 | 0 |
| Leukocytosis, Increase to Grades 2 to 4 | 2 | 0 | 0 | 0 | 0 |
| Leukocytosis, Increase to Grades 3 to 4 | 2 | 0 | 0 | 0 | 0 |
| White blood cell decreased, Increase to Grades 1 to 4 | 22 | 17 | 18 | 19 | 9 |
| White blood cell decreased, Increase to Grades 2 to 4 | 17 | 13 | 13 | 9 | 6 |
| White blood cell decreased, Increase to Grades 3 to 4 | 9 | 7 | 5 | 6 | 4 |
| Lymphocyte count decreased, Increase to Grades 1 to 4 | 18 | 13 | 15 | 6 | 6 |
| Lymphocyte count decreased, Increase to Grades 2 to 4 | 11 | 7 | 9 | 5 | 3 |
| Lymphocyte count decreased, Increase to Grades 3 to 4 | 6 | 4 | 4 | 4 | 1 |
| Lymphocyte count increased, Increase to Grades 1 to 4 | 2 | 2 | 3 | 4 | 0 |
| Lymphocyte count increased, Increase to Grades 2 to 4 | 2 | 2 | 3 | 4 | 0 |
| Lymphocyte count increased, Increase to Grades 3 to 4 | 2 | 2 | 1 | 3 | 0 |
| Neutrophil count decreased, Increase to Grades 1 to 4 | 15 | 12 | 12 | 9 | 5 |
| Neutrophil count decreased, Increase to Grades 2 to 4 | 10 | 7 | 6 | 7 | 4 |
| Neutrophil count decreased, Increase to Grades 3 to 4 | 5 | 4 | 2 | 3 | 4 |
| Platelet count decreased, Increase to Grades 1 to 4 | 24 | 30 | 23 | 21 | 7 |
| Platelet count decreased, Increase to Grades 2 to 4 | 15 | 20 | 12 | 13 | 5 |
| Platelet count decreased, Increase to Grades 3 to 4 | 9 | 13 | 10 | 9 | 4 |
Blood samples were collected for the analysis of clinical chemistry parameters. The parameters were graded according to CTCAE grades. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grades indicate greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increases in grade 1/2/3 to a grade of 4 are presented.
| Participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Alanine aminotransferase increased, Increase to Grades 1 to 4 | 9 | 14 | 12 | 9 | 2 |
| Alanine aminotransferase increased, Increase to Grades 2 to 4 | 2 | 3 | 1 | 1 | 0 |
| Alanine aminotransferase increased, Increase to Grades 3 to 4 | 1 | 0 | 1 | 0 | 0 |
| Hypoalbuminemia, Increase to Grades 1 to 4 | 19 | 15 | 14 | 13 | 7 |
| Hypoalbuminemia, Increase to Grades 2 to 4 | 6 | 9 | 11 | 6 | 2 |
| Hypoalbuminemia, Increase to Grades 3 to 4 | 1 | 2 | 1 | 1 | 0 |
| Alkaline phosphatase increased, Increase to Grades 1 to 4 | 10 | 15 | 8 | 9 | 3 |
| Alkaline phosphatase increased, Increase to Grades 2 to 4 | 1 | 2 | 1 | 1 | 0 |
| Alkaline phosphatase increased, Increase to Grades 3 to 4 | 0 | 0 | 0 | 1 | 0 |
| Aspartate aminotransferase increased, Increase to Grades 1 to 4 | 20 | 23 | 22 | 14 | 3 |
| Aspartate aminotransferase increased, Increase to Grades 2 to 4 | 4 | 3 | 2 | 1 | 0 |
| Aspartate aminotransferase increased, Increase to Grades 3 to 4 | 1 | 0 | 1 | 0 | 0 |
| Blood bilirubin increased, Increase to Grades 1 to 4 | 4 | 4 | 4 | 3 | 3 |
| Blood bilirubin increased, Increase to Grades 2 to 4 | 2 | 0 | 0 | 0 | 1 |
| Blood bilirubin increased, Increase to Grades 3 to 4 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia, Increase to Grades 1 to 4 | 14 | 13 | 15 | 12 | 4 |
| Hypercalcemia, Increase to Grades 2 to 4 | 3 | 2 | 5 | 3 | 1 |
| Hypercalcemia, Increase to Grades 3 to 4 | 3 | 1 | 2 | 2 | 1 |
| Hypocalcemia, Increase to Grades 1 to 4 | 12 | 16 | 8 | 10 | 6 |
| Hypocalcemia, Increase to Grades 2 to 4 | 3 | 4 | 3 | 2 | 1 |
| Hypocalcemia, Increase to Grades 3 to 4 | 1 | 3 | 1 | 1 | 0 |
| CPK increased, Increase to Grades 1 to 4 | 11 | 8 | 5 | 6 | 2 |
| CPK increased, Increase to Grades 2 to 4 | 5 | 3 | 1 | 0 | 0 |
| CPK increased, Increase to Grades 3 to 4 | 2 | 1 | 0 | 0 | 0 |
| Creatinine increased, Increase to Grades 1 to 4 | 14 | 18 | 18 | 15 | 7 |
| Creatinine increased, Increase to Grades 2 to 4 | 6 | 9 | 6 | 7 | 2 |
| Creatinine increased, Increase to Grades 3 to 4 | 0 | 0 | 1 | 0 | 1 |
| Chronic Kidney Disease, Increase to Grades 1 to 4 | 6 | 8 | 8 | 8 | 4 |
| Chronic Kidney Disease, Increase to Grades 2 to 4 | 6 | 6 | 8 | 8 | 4 |
| Chronic Kidney Disease, Increase to Grades 3 to 4 | 3 | 3 | 1 | 3 | 2 |
| GGT increased, Increase to Grades 1 to 4 | 17 | 16 | 16 | 9 | 5 |
| GGT increased, Increase to Grades 2 to 4 | 10 | 7 | 3 | 7 | 1 |
| GGT increased, Increase to Grades 3 to 4 | 2 | 3 | 1 | 3 | 0 |
| Blood lactate dehydrogenase increased, Increase to Grades 1 to 4 | 20 | 19 | 19 | 15 | 6 |
| Blood lactate dehydrogenase increased, Increase to Grades 2 to 4 | 0 | 0 | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased, Increase to Grades 3 to 4 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia, Increase to Grades 1 to 4 | 2 | 3 | 3 | 2 | 0 |
| Hypermagnesemia, Increase to Grades 2 to 4 | 0 | 2 | 2 | 1 | 0 |
| Hypermagnesemia, Increase to Grades 3 to 4 | 0 | 2 | 2 | 1 | 0 |
| Hypomagnesemia, Increase to Grades 1 to 4 | 7 | 3 | 5 | 8 | 2 |
| Hypomagnesemia, Increase to Grades 2 to 4 | 1 | 0 | 0 | 1 | 0 |
| Hypomagnesemia, Increase to Grades 3 to 4 | 1 | 0 | 0 | 0 | 0 |
| Hyperkalemia, Increase to Grades 1 to 4 | 4 | 6 | 7 | 1 | 2 |
| Hyperkalemia, Increase to Grades 2 to 4 | 1 | 2 | 2 | 0 | 0 |
| Hyperkalemia, Increase to Grades 3 to 4 | 1 | 1 | 1 | 0 | 0 |
| Hypernatremia, Increase to Grades 1 to 4 | 4 | 4 | 3 | 5 | 3 |
| Hypernatremia, Increase to Grades 2 to 4 | 1 | 2 | 0 | 1 | 1 |
| Hypernatremia, Increase to Grades 3 to 4 | 1 | 2 | 0 | 1 | 1 |
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Participants | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | 0 | 0 | 0 | 0 | 0 |
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
No measurements were reported for this outcome.
Plasma samples were collected for PK analysis for belantamab mafodotin antibody-drug conjugate (ADC).
| Microgram/ millilitre (ug/mL) | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) for Belantamab Mafodotin Antibody-drug Conjugate (ADC) | 44.8 ± 22.8 | 33.1 ± 23.2 | 42.1 ± 24.7 | 33.1 ± 18.3 | 34.1 ± 26.8 |
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
| ug/mL | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Concentration at 21 Days for Belantamab Mafodotin ADC | 2.28 ± 56.7 | 1.5 ± 62.4 | 1.94 ± 69.3 | 1.69 ± 50.2 | 1.53 ± 62.1 |
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
| ug/mL | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Average Concentration Over 21 Days (Cavg) for Belantamab Mafodotin ADC | 8.4 ± 32.2 | 5.98 ± 34.6 | 7.71 ± 38.6 | 6.3 ± 27.1 | 6.11 ± 40.6 |
Plasma samples were collected to determine the area under the concentration-time curve (AUC) (0-504h) of Belantamab mafodotin ADC.
| micrograms* hour/ millilitre (ug*h/mL) | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Area Under the Concentration-time Curve (AUC) (0-504h) of Belantamab Mafodotin ADC | 4233 ± 32.2 | 3013 ± 34.6 | 3886 ± 38.6 | 3173 ± 27.1 | 3079 ± 40.6 |
Plasma samples were collected for PK analysis of Belantamab mafodotin ADC
| Days | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Half-life (t1/2) of Belantamab Mafodotin ADC | 13 ± 30.5 | 12 ± 32.1 | 12 ± 40 | 12 ± 34.2 | 13 ± 41.3 |
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
| Liter/ days | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Clearance (CL) for Belantamab Mafodotin ADC | 0.8 ± 38.3 | 0.83 ± 57.1 | 0.84 ± 47.7 | 0.74 ± 53.3 | 0.86 ± 59.7 |
Plasma samples were collected for PK analysis for belantamab mafodotin ADC.
| Liter | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Steady-state Volume of Distribution (Vss) for Belantamab Mafodotin ADC | 10.0 ± 19.6 | 9.3 ± 26.4 | 9.4 ± 26.9 | 8.9 ± 25.4 | 10.0 ± 16.1 |
Collected over All-cause mortality, Serious adverse events (SAEs) and non-serious AEs (Non SAEs) were collected up to 152 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | 23/40 (57.5%) | 17/39 (43.6%) | 38/39 (97.4%) |
| Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | 23/40 (57.5%) | 17/40 (42.5%) | 36/40 (90%) |
| Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | 25/40 (62.5%) | 21/39 (53.8%) | 36/39 (92.3%) |
| Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | 21/40 (52.5%) | 16/40 (40%) | 40/40 (100%) |
| Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) | 5/17 (29.4%) | 4/17 (23.5%) | 16/17 (94.1%) |
| Event | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 2/39 | 4/40 | 2/39 | 2/40 | 1/17 |
| PneumoniaInfections and infestations | 2/39 | 3/40 | 3/39 | 2/40 | 1/17 |
| SepsisInfections and infestations | 3/39 | 1/40 | 0/39 | 0/40 | 0/17 |
| GingivitisInfections and infestations | 0/39 | 0/40 | 0/39 | 0/40 | 1/17 |
| Upper respiratory tract infectionInfections and infestations | 0/39 | 0/40 | 0/39 | 1/40 | 1/17 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/39 | 0/40 | 1/39 | 0/40 | 1/17 |
| PyrexiaGeneral disorders | 0/39 | 0/40 | 0/39 | 0/40 | 1/17 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/39 | 0/40 | 0/39 | 0/40 | 1/17 |
| Gingival bleedingGastrointestinal disorders | 0/39 | 0/40 | 0/39 | 0/40 | 1/17 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/39 | 0/40 | 0/39 | 0/40 | 1/17 |
| Event | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) |
|---|---|---|---|---|---|
| Vision blurredEye disorders | 16/39 | 12/40 | 18/39 | 11/40 | 9/17 |
| Dry eyeEye disorders | 15/39 | 12/40 | 12/39 | 12/40 | 8/17 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/39 | 17/40 | 13/39 | 10/40 | 4/17 |
| AnaemiaBlood and lymphatic system disorders | 9/39 | 12/40 | 12/39 | 15/40 | 4/17 |
| Eye irritationEye disorders | 11/39 | 9/40 | 11/39 | 11/40 | 5/17 |
| PhotophobiaEye disorders | 8/39 | 10/40 | 10/39 | 3/40 | 5/17 |
| Foreign body sensation in eyesEye disorders | 7/39 | 7/40 | 11/39 | 5/40 | 3/17 |
| NeutropeniaBlood and lymphatic system disorders | 3/39 | 8/40 | 3/39 | 7/40 | 4/17 |
| Eye painEye disorders | 9/39 | 2/40 | 6/39 | 4/40 | 3/17 |
| NauseaGastrointestinal disorders | 3/39 | 3/40 | 8/39 | 3/40 | 0/17 |
| Age, Continuous(YEARS) | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) | Total |
|---|---|---|---|---|---|---|
| Mean | 66.6 ± 10.36 | 63.0 ± 9.02 | 63.7 ± 9.92 | 65.4 ± 8.87 | 67.1 ± 10.42 | 64.9 ± 9.66 |
| Sex: Female, Male(Participants) | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) | Total |
|---|---|---|---|---|---|---|
| Female | 19 | 21 | 19 | 16 | 8 | 83 |
| Male | 21 | 19 | 21 | 24 | 9 | 94 |
| Race/Ethnicity, Customized(Participants) | Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W) | Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W | Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W) | Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W | Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 13 | 9 | 12 | 6 | 6 | 46 |
| Not Hispanic or Latino | 27 | 31 | 28 | 34 | 11 | 131 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Ran from Mar 2022 to primary completion in Aug 2024, 29 months.
Results were first posted in Oct 2025, 1 year 1 month after primary completion.
Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 29 months is below that.
Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belantamab mafodotin